Compounded GLP-1 Impurities: What Peptide Testing Studies Have Found

No pharmaceutical preparation is 100% pure — not brand-name drugs, not compounded medications, not anything. The relevant question is not whether impurities exist, but what they are, how much is present, and whether the levels fall within safety thresholds established by pharmaceutical science. For compounded GLP-1s, impurity testing has become a battleground between brand-name manufacturers (who cite impurity findings as evidence that compounding is unsafe) and compounding pharmacies (who cite their own testing showing acceptable purity levels).

This article explains what impurities are, how they're measured, what testing has actually found, and what the numbers mean for patients.

Types of Impurities in Compounded Peptides

Related Peptide Impurities

These are the most common category and arise directly from the peptide synthesis process. Semaglutide is a 31-amino acid peptide with a fatty acid side chain — building this molecule step by step inevitably produces small amounts of related but incorrect peptides:

• Deletion peptides: Sequences where one or more amino acids were skipped during synthesis. The resulting peptide is shorter than semaglutide and may have partial or no biological activity.
• Insertion peptides: Sequences where an extra amino acid was incorporated. Less common than deletions but still a known synthetic byproduct.
• Truncation products: Fragments where the synthesis chain broke prematurely, producing a partial peptide.
• Racemized peptides: Peptides where one or more amino acids have the wrong stereochemistry (D-form instead of L-form). This can alter the molecule's binding properties.

These impurities are detected and quantified by HPLC, which separates them from the main semaglutide peak based on their slightly different chemical properties.

Degradation Products

Even a perfectly synthesized peptide can degrade over time, particularly in solution. Common degradation pathways for semaglutide include oxidation (of methionine residues), deamidation (of asparagine residues), and hydrolysis (cleavage of peptide bonds). Degradation products increase over time and with temperature exposure — which is why storage conditions and beyond-use dating matter.

Process-Related Impurities

These come not from the peptide itself but from the materials and processes used in synthesis and compounding:

• Residual solvents: Organic solvents (DMF, TFA, acetonitrile) used in peptide synthesis must be removed to acceptable levels in the final API.
• Reagent byproducts: Coupling agents, protecting groups, and cleavage reagents used during synthesis can leave trace residues.
• Endotoxins: Bacterial membrane fragments that can cause fever and inflammatory responses if present in injectable preparations.
• Particulate matter: Visible or sub-visible particles (fibers, metal fragments, glass) that should not be present in any injectable.

How Impurities Are Measured

The primary analytical tools for peptide impurity profiling are:

• HPLC (High-Performance Liquid Chromatography): The workhorse method. Separates the sample into individual peaks based on chemical properties, quantifies each peak as a percentage of the total. Individual impurity peaks above a threshold (typically 0.5-1.0%) are identified; total impurities are summed.
• LC-MS (Liquid Chromatography-Mass Spectrometry): Combines HPLC separation with mass spectrometric identification. This not only detects impurities but identifies what they are at the molecular level. More informative but more expensive than HPLC alone.
• Residual solvent analysis (GC): Gas chromatography specifically targets and quantifies residual organic solvents against ICH Q3C limits.
• LAL testing: The Limulus Amebocyte Lysate test detects bacterial endotoxins. Results are reported in Endotoxin Units per milligram.

What Testing Has Found

Multiple testing efforts — by pharmacies, independent laboratories, and brand-name manufacturers — have examined compounded GLP-1 preparations. The results paint a nuanced picture:

Well-sourced, well-compounded products from PCAB-accredited pharmacies using API from FDA-registered manufacturers generally show purity profiles comparable to pharmaceutical-grade peptides: total related impurities below 3-5%, no individual impurity above 1.0%, acceptable residual solvent levels, and endotoxin results well below specification limits.

Poorly sourced or poorly compounded products — including some identified in FDA enforcement actions and independent market surveillance — have shown concerning findings: total impurities exceeding 10%, individual unknown impurities above 2%, detectable endotoxins above specification, and in some cases, active ingredient that was not the correct peptide at all.

The spread between best and worst is wide. This is the core argument for pharmacy accreditation and regulatory oversight — the technology to produce high-quality compounded peptides exists, but it requires investment, expertise, and quality systems that not every pharmacy maintains.

What FDA and Manufacturers Have Cited

Novo Nordisk and Eli Lilly have both submitted comments to the FDA citing impurity findings in compounded GLP-1 preparations as evidence against allowing compounding. Some of these submissions included testing of products purchased from online sellers — a mix of licensed pharmacies and unlicensed sellers. The manufacturers' argument is that compounding introduces unacceptable quality variability.

The counterargument from compounding advocates is that the manufacturers' testing often includes products from bad actors (unlicensed sellers, research peptide dealers) alongside legitimate pharmacies — conflating the worst of the market with the industry as a whole. Accredited pharmacies with documented quality programs argue that their products consistently meet pharmaceutical purity standards and that the quality failures cited by manufacturers reflect enforcement gaps, not inherent flaws in compounding.

What Patients Can Take Away

• Impurities in compounded peptides are expected, measured, and managed — not a hidden secret.
• The quality spread between good and bad pharmacies is wider than the quality spread between good pharmacies and brand-name products.
• PCAB accreditation, independent testing, and verifiable certificates of analysis are the practical tools for distinguishing quality operators from the rest.
• If a pharmacy cannot or will not share impurity testing data for its products, that silence is itself informative.

Providers That Prioritize Tested, Documented Quality